BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Protic M, Seibold F, Schoepfer A, Radojicic Z, Juillerat P, Bojic D, Mwinyi J, Mottet C, Jojic N, Beglinger C, Vavricka S, Rogler G, Frei P. The effectiveness and safety of rescue treatments in 108 patients with steroid-refractory ulcerative colitis with sequential rescue therapies in a subgroup of patients. J Crohns Colitis 2014;8:1427-37. [PMID: 24908178 DOI: 10.1016/j.crohns.2014.05.004] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
Number Citing Articles
1 Strong S, Steele SR, Boutrous M, Bordineau L, Chun J, Stewart DB, Vogel J, Rafferty JF; Clinical Practice Guidelines Committee of the American Society of Colon and Rectal Surgeons. Clinical Practice Guideline for the Surgical Management of Crohn's Disease. Dis Colon Rectum 2015;58:1021-36. [PMID: 26445174 DOI: 10.1097/DCR.0000000000000450] [Cited by in Crossref: 65] [Cited by in F6Publishing: 19] [Article Influence: 10.8] [Reference Citation Analysis]
2 Vora R, Finnamore HE, Crook K, Baillie C, Whittle E, Krishnamurthy B, Venkatesh K, Auth MK. Clinical Experience of Use of High-dose Intravenous Methylprednisolone in Children With Acute Moderate to Severe Colitis. Journal of Pediatric Gastroenterology & Nutrition 2016;63:51-7. [DOI: 10.1097/mpg.0000000000001080] [Cited by in Crossref: 6] [Article Influence: 1.0] [Reference Citation Analysis]
3 Bürger M, Schmidt C, Teich N, Stallmach A. Medical Therapy of Active Ulcerative Colitis. Viszeralmedizin 2015;31:236-45. [PMID: 26557831 DOI: 10.1159/000436959] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
4 Gisbert JP, Chaparro M. Acute severe ulcerative colitis: State of the art treatment. Best Pract Res Clin Gastroenterol 2018;32-33:59-69. [PMID: 30060940 DOI: 10.1016/j.bpg.2018.05.007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
5 Pellino G, Keller DS, Sampietro GM, Angriman I, Carvello M, Celentano V, Colombo F, Di Candido F, Laureti S, Luglio G, Poggioli G, Rottoli M, Scaringi S, Sciaudone G, Sica G, Sofo L, Leone S, Danese S, Spinelli A, Delaini G, Selvaggi F; Italian Society of Colorectal Surgery SICCR. Inflammatory bowel disease position statement of the Italian Society of Colorectal Surgery (SICCR): Crohn's disease. Tech Coloproctol 2020;24:421-48. [PMID: 32172396 DOI: 10.1007/s10151-020-02183-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 10.0] [Reference Citation Analysis]
6 Fradet C, Kern J, Atanasov P, Wirth D, Borsi A. Impact of surgery and its complications in ulcerative colitis patients in clinical practice: A systematic literature review of real-world evidence in Europe. International Journal of Surgery Open 2020;22:22-32. [DOI: 10.1016/j.ijso.2019.11.010] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Whaley KG, Rosen MJ. Contemporary Medical Management of Acute Severe Ulcerative Colitis. Inflamm Bowel Dis 2019;25:56-66. [PMID: 29889235 DOI: 10.1093/ibd/izy208] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
8 Chang S, Hanauer S. Optimizing pharmacologic management of inflammatory bowel disease. Expert Review of Clinical Pharmacology 2017;10:595-607. [DOI: 10.1080/17512433.2017.1318062] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
9 Fernández-salazar L, Muñoz F, Barrio J, Muñoz C, Pajares R, Rivero M, Prieto V, Legido J, Bouhmidi A, Herranz M, Fernández N, Sánchez-ocaña R, Joao D, Santos F. Infliximab in ulcerative colitis: real-life analysis of factors predicting treatment discontinuation due to lack of response or colectomy: ECIA (ACAD Colitis and Infliximab Study). Scandinavian Journal of Gastroenterology 2015;51:186-95. [DOI: 10.3109/00365521.2015.1070900] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
10 Szemes K, Soós A, Hegyi P, Farkas N, Erős A, Erőss B, Mezősi E, Szakács Z, Márta K, Sarlós P. Comparable Long-Term Outcomes of Cyclosporine and Infliximab in Patients With Steroid-Refractory Acute Severe Ulcerative Colitis: A Meta-Analysis. Front Med (Lausanne) 2019;6:338. [PMID: 32039218 DOI: 10.3389/fmed.2019.00338] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
11 Xu Y, Tian Y, Wang Y, Yang J, Li F, Wan X, Ouyang M. Human antigen R (HuR) and Cold inducible RNA-binding protein (CIRP) influence intestinal mucosal barrier function in ulcerative colitis by competitive regulation on Claudin1. Biofactors 2021;47:427-43. [PMID: 33638934 DOI: 10.1002/biof.1719] [Reference Citation Analysis]
12 Sedano R, Quera R, Simian D, Yarur AJ. An approach to acute severe ulcerative colitis. Expert Rev Gastroenterol Hepatol 2019;13:943-55. [PMID: 31648574 DOI: 10.1080/17474124.2019.1681974] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
13 Narula N, Jharap B, Colombel J. Management of Severe Ulcerative Colitis. Curr Treat Options Gastro 2015;13:59-76. [DOI: 10.1007/s11938-014-0036-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
14 Dwadasi S, Zafer M, Goens D, Paknikar R, Dalal S, Cohen RD, Pekow J, Rubin DT, Sakuraba A, Micic D. Inpatient Therapy With Calcineurin Inhibitors in Severe Ulcerative Colitis. Inflamm Bowel Dis 2020:izaa326. [PMID: 33319248 DOI: 10.1093/ibd/izaa326] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Kopylov U, Papamichael K, Katsanos K, Waterman M, Bar-Gil Shitrit A, Boysen T, Portela F, Peixoto A, Szilagyi A, Silva M, Maconi G, Har-Noy O, Bossuyt P, Mantzaris G, Barreiro de Acosta M, Chaparro M, Christodoulou DK, Eliakim R, Rahier JF, Magro F, Drobne D, Ferrante M, Sonnenberg E, Siegmund B, Muls V, Thurm T, Yanai H, Dotan I, Raine T, Levin A, Israeli E, Ghalim F, Carbonnel F, Vermeire S, Ben-Horin S, Roblin X. Impact of Infliximab and Cyclosporine on the Risk of Colectomy in Hospitalized Patients with Ulcerative Colitis Complicated by Cytomegalovirus-A Multicenter Retrospective Study. Inflamm Bowel Dis 2017;23:1605-13. [PMID: 28590343 DOI: 10.1097/MIB.0000000000001160] [Cited by in Crossref: 20] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
16 Weisshof R, Ollech JE, El Jurdi K, Yvellez OV, Cohen RD, Sakuraba A, Dalal S, Pekow J, Rubin DT. Ciclosporin Therapy After Infliximab Failure in Hospitalized Patients With Acute Severe Colitis is Effective and Safe. J Crohns Colitis 2019;13:1105-10. [PMID: 30726894 DOI: 10.1093/ecco-jcc/jjz032] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 6.5] [Reference Citation Analysis]
17 Buhl S, Steenholdt C, Rasmussen M, Borghede MK, Brynskov J, Thomsen OØ, Ainsworth MA. Outcomes After Primary Infliximab Treatment Failure in Inflammatory Bowel Disease. Inflamm Bowel Dis 2017;23:1210-7. [PMID: 28445244 DOI: 10.1097/MIB.0000000000001117] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
18 Gionchetti P, Rizzello F. IBD. Sequential rescue therapy in steroid-refractory ulcerative colitis. Nat Rev Gastroenterol Hepatol 2014;11:521-3. [PMID: 25023033 DOI: 10.1038/nrgastro.2014.126] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
19 Sales-Campos H, de Souza PR, Basso PJ, Ramos AD, Nardini V, Chica JE, Capurro ML, Sá-Nunes A, de Barros Cardoso CR. Aedes aegypti salivary gland extract ameliorates experimental inflammatory bowel disease. Int Immunopharmacol 2015;26:13-22. [PMID: 25770821 DOI: 10.1016/j.intimp.2015.03.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
20 Meyer C, Bowers A, Heavener TE, Checketts JX, Vassar M. From clinical practice guideline development to trial registration: A systematic investigation of research pipeline for inflammatory bowel disease. Indian J Gastroenterol 2019;38:247-62. [PMID: 31270778 DOI: 10.1007/s12664-019-00965-4] [Reference Citation Analysis]
21 Zhao HN, Jiang M, Sun MJ, Dai C. The efficacy and safety of infliximab and calcineurin inhibitors in steroid-refractory UC patients: A meta-analysis. Saudi J Gastroenterol 2021;27:191-200. [PMID: 34380865 DOI: 10.4103/sjg.sjg_145_21] [Reference Citation Analysis]
22 Takeuchi K, Shimoyama T, Yamamoto T. Comparison of Safety and Efficacy of Tacrolimus versus Infliximab for Active Ulcerative Colitis. Dig Dis 2018;36:106-12. [PMID: 29050007 DOI: 10.1159/000481815] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
23 Thorne K, Alrubaiy L, Akbari A, Samuel DG, Morrison-Rees S, Roberts SE. Colectomy rates in patients with ulcerative colitis following treatment with infliximab or ciclosporin: a systematic literature review. Eur J Gastroenterol Hepatol 2016;28:369-82. [PMID: 26825217 DOI: 10.1097/MEG.0000000000000568] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]